MapLight Therapeutics Inc（MPLT）のニュースとイベントMPLTMapLight Therapeutics Inc

MapLight Focuses on Advancing ML-007C-MA Progress

"With positive Phase 2 data from ZEPHYR and continued progress in VISTA, we are focusing our efforts on advancing ML-007C-MA in both schizophrenia and ADP," said Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight. "In schizophrenia, ZEPHYR met its primary endpoint and achieved meaningful efficacy results, an encouraging cognitive signal and a tolerability profile designed to translate into real-world use, supporting our planned registrational Phase 3 ZEPHYR-2 trial. In ADP, enrollment in VISTA remains ongoing, with topline results expected in the second half of 2027. Together with our recent private placement and continued focus on capital discipline, we believe we are well positioned to execute on both programs through these key milestones."

MapLight Therapeutics Completes $150M Private Placement Financing

MapLight Therapeutics announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing for gross proceeds of approximately $150M, before deducting placement agent fees and estimated offering expenses. The financing is being led by new and existing institutional investors. In the PIPE, MapLight is selling an aggregate of 9,197,887 shares of its common stock at a price of $11.38 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,983,168 shares of common stock at a purchase price of $11.3799 per pre-funded warrant. Each pre-funded warrant has an exercise price of $0.0001 per share of common stock, will be immediately exercisable, subject to certain conditions set forth in each pre-funded warrant, and will not expire. The PIPE is expected to close on August 14,, subject to customary closing conditions. MapLight intends to use the proceeds from the PIPE primarily to support the continued advancement of ML-007C-MA, including funding the ongoing VISTA Phase 2 study in Alzheimer's disease psychosis as well as the ZEPHYR-2 registrational Phase 3 study in schizophrenia and its associated open-label safety study, and for working capital and other general corporate purposes. The company plans to engage with the FDA at an End-of-Phase 2 meeting to discuss the path forward for ML-007C-MA in schizophrenia, including the design of a Phase 3 trial, which, together with ZEPHYR, would be designed to support a new drug application submission. MapLight's cash, cash equivalents and investments were $351.3M as of June 30. Based on its current operational plans and assumptions, MapLight expects that its existing cash, cash equivalents and investments, together with the net proceeds from the PIPE, will be sufficient to fund the continued advancement of ML-007C-MA through 2028. Morgan Stanley, Jefferies, Leerink Partners and Stifel are acting as placement agents for the PIPE.

Dow Rises, Nasdaq Falls as Market Focuses on Economic Data

The major averages had a mixed day, with the Dow and the S&P 500 higher and Nasdaq in decline amid weakness in tech stocks as the market has reacted positively to easing geopolitical tensions and a steep decline in oil prices.Investor attention is focused on a week that includes the Federal Reserve's July policy meeting, second-quarter GDP data, the June personal consumption expenditures price index, and earnings from four of the "Magnificent Seven" companies. The combination of major economic data and heavyweight earnings is expected to drive market direction through the end of the week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Appleis lobbying the Trump administration to let it use Chinese memory chips, while U.S. supplier Micronis pushing to block the move,ArgenxForte Biosciencesfor $77 per share in cashNaver, Nvidia, and Brookfieldannounced a proposed expansion of, with planned investments that will grow the initial Nvidia DSX AI factory deployment to 200 megawattsMeanwhile, Nvidia is in talks to provide a $250B backstop for OpenAI,Baker Hughesreported2. WALL STREET CALLS:JefferiesFordand General Motorsto BuyRivianto Overweight at Piper SandlerStellantisto Underweight from Overweight at Piper SandlerJPMorganCheck Pointon weaker competitive positionWall Streetcoverage of Bending Spoonswith a mix of Buy and Hold-equivalent ratings3. AROUND THE WEB:Fordhas entered the competition to build the U.S. Army's next-generation tactical truck, WSJ reportsA Chinese state-backed company has begun manufacturing immersion deep ultraviolet lithography machines, a key type of equipment used by chipmakers like TSMCin producing chips, The Information saysParamount Skydanceand Warner Bros. Discoveryremain in limbo as their $81B merger faces an antitrust review that could delay the deal into 2027, limiting strategic moves while the companies focus on legal proceedings and competitors continue to expand, WSJ saysUniCreditCEO Andrea Orcel sees room for an agreement over the bank's proposed takeover of Commerzbank, signaling confidence discussions with the government and stakeholders could lead to a deal, Bloomberg saysTrip.comhas been fined $765M by Chinese regulators after it was concluded that the company abused its market dominance, Bloomberg reports4. MOVERS:D-Wave Quantumgained afterwith AT&TOmerosincreased after AstraZenecareportedof ultomirisGenius Sportswas higher in New York after Goldman Sachscoverage of the stock with a Buy ratingCapricor Therapeuticswas lower after the FDAMapLight Therapeuticsfell after announcing results from its5. EARNINGS/GUIDANCE:AstraZenecaand reaffirmed its guidance for FY26, with CEO Pascal Soriot commenting on "strong performance and continued pipeline delivery" in the first halfEnsign Groupand raised its outlook for FY26Bank of Marin, with EPS beating consensusBank of Hawaii, with CEO Jim Polk calling them "solid"Sierra Bancorp, with EPS missing consensusINDEXES:The Dow rose 262.83, or 0.51%, to 52,210.08, the Nasdaq lost 43.74, or 0.18%, to 24,932.08, and the S&P 500 advanced 1.20, or 0.02%, to 7,413.18.